# US 2022/0235330 A1 · Methods for creating integration-free, virus-free, exogenous oncogene-free ips cells and compositions for use in such methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0235330 A1
- Document ID: US20220235330A1
- Status: Published application
- Kind: A1
- Application number: 17/591,340
- Filed: 2022-02-02
- Published: 2022-07-28
- Earliest claimed: 2018-04-16
- Assignees: Cellular Engineering Technologies, Inc.
- Applicants: Cellular Engineering Technologies, Inc.
- Inventors: Alan B. MOY; Anant KAMATH
- Web page: https://patentgrep.com/patent/US20220235330A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 15/85: for animal cells
- C12N 2310/11: Antisense
- C12N 2330/51: Specially adapted vectors
- C12N 2500/92: Medium free of human- or animal-derived components
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2506/09: from epidermal cells, from skin cells, from oral mucosa cells
- C12N 2506/11: from blood or immune system cells
- C12N 2506/115: from monocytes, from macrophages
- C12N 2510/00: Genetically modified cells
- C12N 2710/00041: Use of virus, viral particle or viral elements as a vector
- C12N 2800/108: episomal vectors
- C12N 2800/24: Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- C12N 2820/60: from viruses
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods are disclosed for reprogramming a somatic cell, including an adherent cell and a cell in suspension, into an induced pluripotent stem comprising expressing exogenous Sox-2, exogenous Klf-4, exogenous Oct3/4 from DNA that has not integrated into the genome of the somatic cell, suppressing p53 activity within the somatic cell, and exposing the somatic cell to reprogramming-assistance factors comprising an exogenous Alk-5 inhibitor, an exogenous histone deacetylase inhibitor, and an exogenous activator of glycolysis. Compositions and kits for use in such methods are also disclosed as are cells made by such a method.

## Claims

### Claim 1

A method for reprogramming a somatic cell comprising:
culturing a somatic cell comprising one or more non-integrating vectors encoding Sox-2, Klf-4, and Oct3/4 in a reprogramming medium comprising an exogenous Alk-5 inhibitor, an exogenous histone deacetylase inhibitor, an exogenous activator of glycolysis, and exogenous ascorbic acid; and
obtaining an integration-free, virus-free, exogenous oncogene-free induced pluripotent stem (iPS) cell.

### Claim 2 (depends on 1)

The method for reprogramming a somatic cell according to claim 1, wherein the one or more non-integrating vectors also encode EBNA-1.

### Claim 3 (depends on 1)

The method for reprogramming a somatic cell according to claim 1, further comprising maintaining the obtained iPS cell in a dedifferentiation maintenance medium comprising basic fibroblast growth factor and transforming growth factor beta after being cultured in the reprogramming medium.

### Claim 4 (depends on 1)

The method for reprogramming a somatic cell according to claim 1, wherein the culturing does not require feeder cells.

### Claim 5 (depends on 1)

The method for reprogramming a somatic cell according to claim 1, wherein
the Alk-5 inhibitor comprises 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (A83-01), 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide, 4-[4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, or 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline;
the histone deacetylase inhibitor comprises sodium butyrate or valproic acid; and
the activator of glycolysis comprises 5-(4-Chloro-phenyl)-3-phenyl-pent-2-enoic acid (PS48); α,α,-Dimethyl-4-[2-methyl-8-[2-(3-pyridinyl)ethynyl]-1H-imidazo[4,5-c]quinolin-1-yl]-benzeneacetonitrile (BAG956); N-[3-[[5-Iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide (BX795); (3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide (GSK 2334470); 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide (OSU03012); or 4-Dodecyl-N-1,3,4-thiadiazol-2-yl-benzenesulfonamide (PHT427).

### Claim 6 (depends on 5)

The method for reprogramming a somatic cell according to claim 5, wherein the Alk-5 inhibitor comprises A83-01, the histone deacetylase inhibitor comprises sodium butyrate, and the activator of glycolysis comprises PS48.

### Claim 7 (depends on 1)

The method for reprogramming a somatic cell according to claim 1, wherein the somatic cell is a human cell and reprogramming efficiency exceeds 0.0006%.

### Claim 8

A composition comprising a somatic cell and a cell culture medium, the somatic cell comprising episomal polynucleotides encoding Sox-2, Klf-4, and Oct3/4, and the medium comprising an exogenous Alk-5 inhibitor, an exogenous histone deacetylase inhibitor, an exogenous activator of glycolysis, and exogenous ascorbic acid.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein the somatic cell further comprises an episomal polynucleotide encoding EBNA-1.

### Claim 10 (depends on 8)

The composition according to claim 8, wherein the somatic cell is a human cell.

### Claim 11 (depends on 8)

The composition according to claim 8, wherein the medium or the somatic cell further comprises an agent for inhibiting p53 activity.

### Claim 12 (depends on 11)

The composition according to claim 11, wherein the agent for inhibiting p53 activity comprises a compound selected from pifithrin-α, cyclic pifithrin-α, pifithrin-μ, RITA, SJ 172550, nutlin-3, a pharmaceutically acceptable salt of one of the aforementioned compounds, or an antisense oligonucleotide.

### Claim 13 (depends on 8)

The composition according to claim 8, wherein
the Alk-5 inhibitor comprises 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (A83-01), 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide, 4-[4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, or 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline;
the histone deacetylase inhibitor comprises sodium butyrate or valproic acid; and
the activator of glycolysis comprises 5-(4-Chloro-phenyl)-3-phenyl-pent-2-enoic acid (PS48); α,α,-Dimethyl-4-[2-methyl-8-[2-(3-pridinyl)ethynyl]-1H-imidazo[4,5-c]quinolin-1-yl]-benzeneacetonitrile (BAG956); N-[3-[[5-Iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide (BX795); (3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide (GSK 2334470); 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide (OSU03012); or 4-Dodecyl-N-1,3,4-thiadiazol-2-yl-benzenesulfonamide (PHT427).

### Claim 14 (depends on 13)

The composition according to claim 13, wherein the Alk-5 inhibitor comprises A83-01, the histone deacytylase inhibitor comprises sodium butyrate, and the activator of glycolysis comprises PS48.

### Claim 15

A kit comprising:
(a) one or more non-integrating vectors encoding Sox-2, Klf-4, and Oct3/4;
(b) an Alk-5 inhibitor,
(c) a histone deacetylase inhibitor,
(d) an activator of glycolysis, and
(e) ascorbic acid.

### Claim 16 (depends on 15)

The kit according to claim 15, wherein the one or more non-integrating vectors also encode EBNA-1.

### Claim 17 (depends on 15)

The kit according to claim 15, which further comprises an agent for inhibiting p53 activity.

### Claim 18 (depends on 17)

The kit according to claim 17, wherein the agent for inhibiting p53 activity comprises a compound selected from pifithrin-α, cyclic pifithrin-α, pifithrin-μ, RITA, SJ 172550, nutlin-3, a pharmaceutically acceptable salt of one of the aforementioned compounds, or an antisense oligonucleotide.

### Claim 19 (depends on 15)

The kit according to claim 15, wherein
the Alk-5 inhibitor comprises 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (A83-01), 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide, 4-[4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, or 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline;
the histone deacetylase inhibitor comprises sodium butyrate or valproic acid; and
the activator of glycolysis comprises 5-(4-Chloro-phenyl)-3-phenyl-pent-2-enoic acid (PS48); α,α,-Dimethyl-4-[2-methyl-8-[2-(3-pridinyl)ethynyl]-1H-imidazo[4,5-c]quinolin-1-yl]-benzeneacetonitrile (BAG956); N-[3-[[5-Iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide (BX795); (3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide (GSK 2334470); 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide (OSU03012); or 4-Dodecyl-N-1,3,4-thiadiazol-2-yl-benzenesulfonamide (PHT427).

### Claim 20 (depends on 19)

The kit according to claim 19, wherein the Alk-5 inhibitor comprises A83-01, the histone deacetylase inhibitor comprises sodium butyrate, and the activator of glycolysis comprises PS48.
